Ohm Birte, Jungraithmayr Wolfgang
Department of Thoracic Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
Front Immunol. 2022 Mar 7;13:845867. doi: 10.3389/fimmu.2022.845867. eCollection 2022.
Allograft rejection remains the major hurdle in lung transplantation despite modern immunosuppressive treatment. As part of the alloreactive process, B cells are increasingly recognized as modulators of alloimmunity and initiators of a donor-specific humoral response. In chronically rejected lung allografts, B cells contribute to the formation of tertiary lymphoid structures and promote local alloimmune responses. However, B cells are functionally heterogeneous and some B cell subsets may promote alloimmune tolerance. In this review, we describe the current understanding of B-cell-dependent mechanisms in pulmonary allograft rejection and highlight promising future strategies that employ B cell-targeted therapies.
尽管有现代免疫抑制治疗，同种异体移植排斥仍然是肺移植的主要障碍。作为同种异体反应过程的一部分，B细胞越来越被认为是同种异体免疫的调节因子和供体特异性体液反应的启动者。在慢性排斥的肺同种异体移植中，B细胞有助于三级淋巴结构的形成并促进局部同种异体免疫反应。然而，B细胞在功能上是异质性的，一些B细胞亚群可能促进同种异体免疫耐受。在这篇综述中，我们描述了目前对肺同种异体移植排斥中B细胞依赖性机制的理解，并强调了采用B细胞靶向疗法的有前景的未来策略。
